A new dimension of therapeutic design: Glycans
Kyron Bio unlocks precise, programmable control over N-glycans, enabling new therapeutic design choices that can improve efficacy, stability and functionality.
Most therapeutics leave glycosylation up to chance
N-glycans are naturally occurring sugar structures found on half the proteins in the human body, as well as on many therapeutics. They can influence how a therapeutic behaves in the body, how long it stays active, and how it interacts with the immune system.
However, glycans are naturally messy. A single batch of antibody contains a wide mixture, making their impact on therapeutic performance hard to predict and control.
We can program where glycans are and what they do
Our platform combines computational protein design with glycoengineered cell lines to control N-glycan structure and introduce new N-glycans at precisely defined positions on therapeutic proteins.
Instead of accepting glycosylation as an outcome, we design it as a feature.
Our technology lets us control what biologics can achieve
Our platform combines cell-line engineering to precisely control N-glycan structure with in silico design to introduce new N-glycans at defined sites on therapeutic proteins.
By controlling both N-glycan structure and location, we can tune therapeutic properties and introduce new functionality, opening up design possibilities beyond the protein sequence alone.
Developing a new class of antibody therapeutics
Our multidisciplinary team combines glycobiologists, protein engineers, cell line developers, computational scientists and therapeutic development experts, supported by leading advisors, all working towards a shared ambition to make better therapies for patients.
Latest updates
Paris Biotech Santé - Site Cochin
27 rue du Faubourg Saint Jacques
75014 Paris, France